Kenvue Inc. (NYSE:KVUE) Shares Sold by Levin Capital Strategies L.P.

Levin Capital Strategies L.P. cut its holdings in Kenvue Inc. (NYSE:KVUE) by 79.3% during the fourth quarter, HoldingsChannel reports. The firm owned 24,326 shares of the company’s stock after selling 93,151 shares during the period. Levin Capital Strategies L.P.’s holdings in Kenvue were worth $524,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of KVUE. Clearstead Advisors LLC acquired a new position in Kenvue in the third quarter valued at $25,000. Planned Solutions Inc. acquired a new position in shares of Kenvue during the fourth quarter worth about $27,000. Venturi Wealth Management LLC acquired a new position in shares of Kenvue during the third quarter worth about $28,000. EverSource Wealth Advisors LLC purchased a new stake in Kenvue during the third quarter worth about $28,000. Finally, Cullen Frost Bankers Inc. purchased a new stake in Kenvue during the third quarter worth about $29,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. JPMorgan Chase & Co. reduced their price target on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. William Blair began coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating for the company. Sanford C. Bernstein initiated coverage on shares of Kenvue in a research report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target on the stock. The Goldman Sachs Group started coverage on shares of Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 target price on the stock. Finally, Royal Bank of Canada decreased their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average price target of $24.85.

Kenvue Price Performance

Shares of NYSE:KVUE traded up $0.27 during trading on Thursday, reaching $19.12. 10,314,411 shares of the stock were exchanged, compared to its average volume of 16,631,246. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78. Kenvue Inc. has a 1-year low of $17.82 and a 1-year high of $27.80. The stock has a fifty day moving average of $19.82 and a two-hundred day moving average of $20.12.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.03. The business had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. Sell-side analysts anticipate that Kenvue Inc. will post 1.15 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th will be issued a dividend of $0.20 per share. The ex-dividend date is Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a yield of 4.18%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.